Why are long-acting beta-adrenoceptor agonists long-acting?
about
N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transportInvestigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease.Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation.Anticholinergic bronchodilators in combination.Long-acting inhaled beta(2)-agonist therapy in asthma.Inhalation of beta 2 agonists impairs the clearance of nontypable Haemophilus influenzae from the murine respiratory tract.Different effects of salmeterol, formoterol and salbutamol on cholinergic responses in the ferret trachea.Quantitative autoradiographic studies of relaxin binding in rat atria, uterus and cerebral cortex: characterization and effects of oestrogen treatmentDesensitisation of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol.Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA).Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose.Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjectsLong-acting beta2-agonists: comparative pharmacology and clinical outcomes.Pharmacogenomics of long-acting β2-agonists.Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.The effects of formoterol on plasma exudation produced by a localized acute inflammatory response to bradykinin in the tracheal mucosa of rats in vivo.Extent of salmeterol-mediated reassertion of relaxation in guinea-pig trachea pretreated with aliphatic side chain structural analogues.Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease.The dopamine D1 receptor is expressed and facilitates relaxation in airway smooth muscle.On the mechanism of the persistent action of salmeterol: what is the current position?Effects of asthma treatment: the present and future.Third-generation long-acting β₂-adrenoceptor agonists: medicinal chemistry strategies employed in the identification of once-daily inhaled β₂-adrenoceptor agonists.Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease.Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.Inhaled β2-agonists in asthma management: an evolving story.Long Receptor Residence Time of C26 Contributes to Super Agonist Activity at the Human β2 Adrenoceptor.Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivoFormoterol fumarate inhalation solution (Perforomist) for COPD.Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterolEffect of COPD treatments on MRP1-mediated transport in bronchial epithelial cells.Airway smooth muscle relaxation.Airway smooth muscle tone modulates mechanically induced cytoskeletal stiffening and remodeling.Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.Thiazolidinediones inhibit airway smooth muscle release of the chemokine CXCL10: in vitro comparison with current asthma therapies.Correlation of cyclic AMP accumulation and relaxant actions of salmeterol and salbutamol in bovine tracheal smooth muscle.Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations.Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists
P2860
Q28365362-8F767459-A542-45E1-A286-C211D35B2683Q30397854-874C4608-3D85-49A3-8D98-C38BB3EC2199Q33860283-63109265-CB17-49EC-B4FF-EA22C9B3B7B6Q34181783-62FDF65C-225F-4B77-BED8-08DC055207C4Q34392656-A46B090A-B1B1-46CD-883F-207605AC0712Q34590657-D6D124C7-0A22-46E2-A674-3097EC13A069Q34793042-DF53D26E-B7B3-445E-94A1-9948577E5BAFQ35028783-59F82723-5223-4C27-BC06-A9FE30B54EB8Q35046032-9D726F54-374C-492C-BCCA-0B2BF761F044Q35088023-A7CB3A1D-8D65-4FDF-A4F7-2A51C2BCDECBQ35535393-0E393B05-AD07-4C3C-82ED-969E87345268Q35563595-538EBBB4-9F7C-4235-9607-A39875CC50C2Q35627925-AB7D34F7-6393-4DD3-A8D5-54CC39C8C7CBQ35734012-1315FE27-A3E7-4FE4-B8BC-7B5CBF5B40BEQ35768436-33F22C59-4D2B-40B0-9FAC-2568B3D3F798Q35872752-12D5241E-0663-4D40-87B8-A41E4D600CDEQ35873966-927053D5-65AB-4A22-BBCB-1BF230352C4FQ36301610-36FD9E71-920D-4DE8-BAF3-E4E0241BE5BAQ37357146-539256A1-081B-41AA-B4C9-E90872035D3AQ37589710-7F1066ED-1CF7-4703-A522-0CF7CC25F722Q37755242-BEA4767B-9F7B-4BF6-9D45-0A0084C41587Q37937552-0F8D820C-2CB5-4EA5-BDBF-FA63D6EB199CQ37983747-7BD5C4A2-FCE1-4BAD-8CE9-8CDC8DCB01F1Q38241442-05877A69-F894-4D79-9111-0901AFDCC249Q38248438-86334B24-FE13-4097-BD28-BE812E287ED0Q38447368-A5A305DD-1EA7-4144-8452-665EEEE1A6EDQ38756326-BC815F43-C108-4D82-8C90-3868DFB159D8Q38803217-547578B3-11BE-4FEB-BC9A-ED8B83349C67Q38822818-B394F2FD-C87D-4B68-9449-E7D2B731A213Q39317855-0D2958B3-686B-46F7-8CB0-B99922667F45Q39782286-62304137-3E53-4363-8EF8-D1B5FB2C319BQ39826205-5EA4FE33-7BFC-4A15-B290-EDECD7DBFD15Q39920199-5EA41108-C67D-472C-B598-6701F73DD4FAQ40419425-5105C87F-8BB6-4C17-A6A6-BA9A1D25FD08Q40432038-BBF1AD72-0D8A-4409-9CF1-4FBEE1EDCCEBQ41121806-51E761E7-57CD-4E3C-AD09-D88AAA68A6C5Q41681579-8B69132B-B2D6-4350-9D7A-1FB91AD8239BQ41980233-2CF8F79C-2F1F-4700-BBBA-B07BFDE5EB83Q41984226-6F900B81-3581-4394-B64E-9814A0375038Q42283741-3A5A2DC9-1C59-4AE3-A3CB-F0BE58CEBB71
P2860
Why are long-acting beta-adrenoceptor agonists long-acting?
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Why are long-acting beta-adrenoceptor agonists long-acting?
@ast
Why are long-acting beta-adrenoceptor agonists long-acting?
@en
Why are long-acting beta-adrenoceptor agonists long-acting?
@nl
type
label
Why are long-acting beta-adrenoceptor agonists long-acting?
@ast
Why are long-acting beta-adrenoceptor agonists long-acting?
@en
Why are long-acting beta-adrenoceptor agonists long-acting?
@nl
prefLabel
Why are long-acting beta-adrenoceptor agonists long-acting?
@ast
Why are long-acting beta-adrenoceptor agonists long-acting?
@en
Why are long-acting beta-adrenoceptor agonists long-acting?
@nl
P2093
P1476
Why are long-acting beta-adrenoceptor agonists long-acting?
@en
P2093
P304
P356
10.1183/09031936.94.07030569
P577
1994-03-01T00:00:00Z